Several years observations with Mydocalm muscle relaxant in locomotor disease patients.
Two therapeutic methods were compared on locomotor disease patients; the currently used anti-inflammatory complex therapy and the same therapy complemented with Mydocalm. On the basis of the changes of pain indices and motion indices chosen as parameters it could be concluded that Mydocalm is a valuable adjuvant, especially in improving locomotor functions, and it promotes the improvement of the general condition of the patients and the performance of their daily activities by relieving muscular hypertonia and contractures.
Gálos
G
G
Municipal St. István Hospital-Outpatient Clinic, Budapest.
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005684:Gait; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D026741:Physical Therapy Modalities / Q000592:standards; D012216:Rheumatic Diseases / Q000150:complications*; D012720:Severity of Illness Index; D014049:Tolperisone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014049:Tolperisone